Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer - Wikidata - wikimedia - TriplyDB

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

http://www.wikidata.org/entity/Q24642049

about

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach Chemophototherapy: An Emerging Treatment Option for Solid Tumors Potential role of vascular targeted therapy to combat against tumor.DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation Therapeutic advances in women's cancers Targeting the tumor vascular supply with vascular disrupting agents Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.Antivascular agents for non-small-cell lung cancer: current status and future directions.The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Combretastatin A4 phosphate: a novel vascular disrupting agent.Tumor vasculature as target for therapeutic intervention.ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).Emerging antiangiogenic therapies for non-small-cell lung cancer.Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.Targeting VEGF in lung cancer.Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?Vascular-disrupting agents in oncology.Recent advances in vascular disrupting agents in cancer therapy.Anti-angiogenesis in Personalized Therapy of Lung Cancer.New therapies for chronic hepatitis B.Natural products against cancer angiogenesis.Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?

P2860

Q28388409-8AF192B7-425C-4763-8CB6-B040F155934A Q28468315-ADB62FAB-BE20-4B4A-8766-0E81E9B08219 Q33470615-F314B876-DE31-4C57-9354-DBF823ADD126 Q33773787-D289573F-4DF7-4610-BE5E-D306A707C6B9 Q33796126-0AD53920-E754-4F3C-A264-7941AE585E58 Q33820595-90F9520B-6C50-4118-BD3B-BE5B38D00C72 Q33989239-982CCE7B-67FF-469B-8B70-0FAF295D211F Q34122191-0A106910-1D9D-4792-815E-BAE357B37E4F Q34122854-0E379A78-1B36-449A-BABF-ECF1C4CA2FC5 Q34134062-045784EC-C9DA-4358-958A-899167B77C21 Q34208140-85BBD8D0-F737-43AF-822C-DBA7D46E0E1D Q34303159-DD065376-9D1D-4908-8FAD-448888473321 Q34303312-343142AD-D82F-47C2-A9AE-7A2E9CB58324 Q34551903-4EF310EA-B6AF-4FAB-8F44-62E07C5FBC3E Q34653072-FDE420C8-AF4C-4C2D-A4F8-984E8990ED62 Q35317995-68596C4A-4E38-4037-A159-1835996DE335 Q35418973-06E15A2F-AE02-403B-A36B-AA0F69EF5B66 Q35667726-A9C16AE0-5209-46AB-858B-7811E92EF5FA Q35832390-129BC4AA-CE43-46E5-BF34-D091803EC120 Q36641876-17C97DA4-401B-4DCD-BAE6-543FD9088F44 Q36999705-3C600DD1-1DB1-4BCE-8494-80F819CDC488 Q37154148-AACF3C4F-D528-48D8-9225-70C5064FAFAF Q37313683-840138E5-5B7E-4A8F-B040-DCEECC703506 Q37474683-2183FE82-F238-4DEF-9F7D-428EA961EB35 Q37624732-B84DD829-A0B4-4765-835B-793B52F84B98 Q37668618-12D7B34F-4033-4DC7-9607-A980F77D9020 Q37783616-951AAF15-68A4-40D3-8B23-20928AD221F0 Q37800110-1AF62CEF-6130-4CC2-B1C2-062D2D8ADD92 Q37808216-1A047965-3F21-4782-A214-C21E15307390 Q37922775-4C7073F5-E3C0-42DB-9ED3-E1E31975B5FF Q37945645-78185414-E222-42F4-9D29-B5D6BE62403E Q37986608-41B479DA-B6C5-41AB-A139-9067A14B6BC2 Q37996080-99BAD7F4-27DC-45F3-919F-0BD69F336C2B Q38000486-5B1FA69A-07CF-4C6A-8D93-4B84AE63D844 Q38073812-C7855BD6-5F2E-4070-BF86-A420E910084C Q38264533-1BE98BD6-87DE-462C-BBD3-B870B01F94A3 Q38669276-0358349E-D148-49B1-87FB-935579D2F677 Q38725759-3AF51F9C-5238-4098-AB24-D30A89FBDAA0 Q38960257-FFA63C2F-F1EC-4825-B120-68508F54FFE7 Q40340984-B615C310-7DE0-4761-AB64-6A6836DE1FD9

P2860

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

http://www.wikidata.org/entity/Q24642049

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Randomised phase II study of A ...... ced non-small cell lung cancer

@ast

Randomised phase II study of A ...... ced non-small cell lung cancer

@en

Randomised phase II study of A ...... ced non-small cell lung cancer

@nl

type

label

Randomised phase II study of A ...... ced non-small cell lung cancer

@ast

Randomised phase II study of A ...... ced non-small cell lung cancer

@en

Randomised phase II study of A ...... ced non-small cell lung cancer

@nl

prefLabel

Randomised phase II study of A ...... ced non-small cell lung cancer

@ast

Randomised phase II study of A ...... ced non-small cell lung cancer

@en

Randomised phase II study of A ...... ced non-small cell lung cancer

@nl

P1433

Q24642049-BE146C94-CDF6-4DBB-B1FB-DA046B57515D

P1476

Q24642049-000D7639-5E3B-492D-8BAA-E8FC38BE05E7

P2093

Q24642049-00BA2746-C25C-4D5D-9B25-5049F68CC478

Q24642049-0F7FAFF3-D8D4-4F47-8470-6A537D4B0F9F

Q24642049-17DB8DD2-B9B5-4FD2-9E19-4ECD7AF49C53

Q24642049-6110E012-0F68-4835-82FD-B3DA95851A22

Q24642049-9339CE5A-CF8D-4452-AAA9-4F8534DEE248

Q24642049-AD1CFE61-98CC-4B15-B006-38D8D9A5D4A5

Q24642049-D1BAB1DC-A01B-4875-9710-F239A584B6FD

Q24642049-D3BC41DF-C57B-457B-89DA-96BDF4E66660

Q24642049-EF505AF8-5911-42E2-A488-E823FADD7C96

Q24642049-F8C36593-9E80-4033-9482-2FB81E8A0F07

P2860

Q24642049-0127679C-961C-468C-8228-3CD14F235E8A

Q24642049-045AF301-E5CA-4067-AE09-2BAC47BEA112

Q24642049-149D3501-1DF4-4C76-8D21-83BEC2E39AC6

Q24642049-407FF269-C0E2-47E1-895F-05E211253DEC

Q24642049-4CD59242-8D20-457E-B2AA-71E7E9752C31

Q24642049-50F4D3CA-DB87-455A-95CC-253C7DCA1EC7

Q24642049-6B5707C5-8A5D-448F-9626-50731695B3CE

Q24642049-7B8C1F8E-A64E-4C7B-85A5-1D91B343E13E

Q24642049-934C4FBA-A960-4D9B-93FB-683CA7259A2E

Q24642049-9940BF0A-B00C-4F2C-B9E3-619BD41E4BE9

P2888

Q24642049-298605D3-3335-41EE-AC2E-027C07C5038A

P304

Q24642049-B0F2FC61-A146-4458-97A7-CC99E4F6DE08

P31

Q24642049-A92EB2CB-E827-439F-9B64-DCF3557537E5

P3181

Q24642049-23F63C32-FA1C-420E-A9FB-B8AD65B246D0

P356

Q24642049-7C9AAB48-6117-4F6D-BCE0-D954E8EFFCC2

P407

Q24642049-0EAF99B8-5493-4905-88C0-8DB2403976D9

P433

Q24642049-F3A6EE6F-5A32-4D4B-B1FD-1677755945C2

P478

Q24642049-AE5407B7-8F54-41B1-B56F-78B7D658F37D

P50

Q24642049-3EE2FD99-C1F2-45E8-BA0D-5426B1803E61

Q24642049-47D979C9-4D40-46D6-A38B-788A3D7F8FE5

P577

Q24642049-475DE8FB-72CE-4E03-A6AA-ECFE1B488D5E

P5875

Q24642049-F719844F-6554-4442-83FD-27BA5CCF2426

P6179

Q24642049-ADA1C404-70AA-429C-A6AC-F12172457EBE

P698

Q24642049-56E51C01-F688-4ED7-B850-428E404E36D8

P932

Q24642049-135F14D8-3617-4531-819C-65275EF9810B

P3181

P356

P1433

British Journal of Cancer

P1476

Randomised phase II study of A ...... ced non-small cell lung cancer

@en

P2093

D Gibbs

http://www.w3.org/2001/XMLSchema#string

E Quoix

http://www.w3.org/2001/XMLSchema#string

J Von Pawel

http://www.w3.org/2001/XMLSchema#string

J-J Lafitte

http://www.w3.org/2001/XMLSchema#string

L Freitag

http://www.w3.org/2001/XMLSchema#string

M A Rosenthal

http://www.w3.org/2001/XMLSchema#string

M B Jameson

http://www.w3.org/2001/XMLSchema#string

M Reck

http://www.w3.org/2001/XMLSchema#string

M Serke

http://www.w3.org/2001/XMLSchema#string

P N Mainwaring

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Antivascular therapy of cancer: DMXAA.

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.

P2888

P304

2006-2012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4820013

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJC.6604808

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Christos Chouaid

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23659811

http://www.w3.org/2001/XMLSchema#string

P6179

1022476136

http://www.w3.org/2001/XMLSchema#string

P698

19078952

http://www.w3.org/2001/XMLSchema#string

P932

2607218

http://www.w3.org/2001/XMLSchema#string